Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Bio-Rad Laboratories; Cellzome, GlaxoSmithKline; Ambry Genetics; Horizon Discovery, Eppendorf

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment Bank Leerink Swann this week upgraded its rating on Bio-Rad Laboratories' stock from "market perform" to "outperform," citing a favorable trend for the firm's diagnostics business over the immediate term. The bank also placed a 12-month valuation range of between $107 and $114 on the stock. Bio-Rad closed Wednesday, the day the note was issued, at $98.75.


Cellzome said this week that it has achieved the first milestone in its epigenetics alliance with GlaxoSmithKline. The firms have been using Cellzome's Episphere technology to identify small-molecule drug targets from four different epigenetic target classes. The firm said that the milestone will trigger a payment from GlaxoSmithKline, but it did not disclose the amount.


Ambry Genetics said on Thursday that it has launched next-generation sequencing services using Illumina's HiSeq 2000 platform. It noted that it has been an early adapter of Illumina sequencing systems since 2007 and also serves as a certified service provider for Illumina platforms.


Horizon Discovery has licensed worldwide exclusive rights to a panel of new human isogenic cell models developed by Zhenghe Wang, an assistant professor of genetics at Case Western Reserve University School of Medicine. The cell lines were developed using the firm's rAAV Genesis gene-editing platform and will be added to Horizon’s library of more than 300 X-MAN cell models. The license initially runs for 10 years and includes up-front fees and an ongoing royalty on product sales.


The Genome Center at Washington University has bought and installed 10 additional Eppendorf epMotion 5075 TMX PC automated pipetting systems for next-generation sequencing sample preparation on the Illumina GA IIx and HiSeq platforms.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.